Cellectar Biosciences, Inc. (CLRB)
2.40
-0.01
(-0.41%)
USD |
NASDAQ |
Sep 09, 12:39
Cellectar Biosciences Debt to Equity Ratio : 0.0513 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0513 |
| March 31, 2026 | 0.3241 |
| December 31, 2025 | 0.0413 |
| September 30, 2025 | 0.046 |
| June 30, 2025 | 0.0607 |
| March 31, 2025 | 0.0492 |
| December 31, 2024 | 0.0315 |
| September 30, 2024 | 0.031 |
| June 30, 2024 | 0.0386 |
| March 31, 2024 | 0.0395 |
| December 31, 2023 | -0.0401 |
| September 30, 2023 | 0.1246 |
| June 30, 2023 | -1.252 |
| March 31, 2023 | 0.0817 |
| December 31, 2022 | 0.0633 |
| September 30, 2022 | 0.0158 |
| June 30, 2022 | 0.0117 |
| March 31, 2022 | 0.0103 |
| December 31, 2021 | 0.0091 |
| September 30, 2021 | 0.0086 |
| June 30, 2021 | 0.0083 |
| March 31, 2021 | 0.0079 |
| December 31, 2020 | 0.0055 |
| September 30, 2020 | 0.0391 |
| June 30, 2020 | 0.033 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0957 |
| December 31, 2019 | 0.0582 |
| September 30, 2019 | 0.0451 |
| June 30, 2019 | 0.036 |
| March 31, 2019 | 0.0609 |
| December 31, 2018 | 0.0002 |
| September 30, 2018 | 0.0002 |
| June 30, 2018 | 0.0008 |
| March 31, 2018 | 0.0006 |
| December 31, 2017 | 0.0005 |
| September 30, 2017 | 0.0008 |
| June 30, 2017 | 0.0006 |
| March 31, 2017 | 0.0005 |
| December 31, 2016 | 0.007 |
| September 30, 2016 | 0.0203 |
| June 30, 2016 | 0.0222 |
| March 31, 2016 | 0.1085 |
| December 31, 2015 | 0.2064 |
| September 30, 2015 | 0.59 |
| June 30, 2015 | 0.1943 |
| March 31, 2015 | 0.1007 |
| December 31, 2014 | 0.0431 |
| September 30, 2014 | 0.0469 |
| June 30, 2014 | -1.672 |
| March 31, 2014 | -5.797 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 36.64M |
| Total Liabilities (Quarterly) | 6.767M |
| Shareholders Equity (Quarterly) | 29.87M |
| Current Ratio | 6.659 |
| Net Debt Paydown Yield | -0.92% |